title: Magnesium efficacy in magnesium deficient and nondeficient patients with rapid ventricular response atrial fibrillation.
abstract: We assessed the effect of magnesium sulphate (MgSO4) on lowering the rate in ventricular atrial fibrillation (AF), and evaluated the effect of this therapy in magnesium (Mg) deficient and nondeficient patients. This experimental clinical study was performed on 34 patients with rapid AF (ventricular rate [VR] > 120/minute) presenting to the emergency department of a tertiary care university hospital. Patients with systolic blood pressure < or = 100 mmHg, Hb level < or = 11.8, saO2 of < or = 96%, BUN > or = 40 or creatine > or = 1.8 were excluded (n = 15). Nineteen patients were given an initial 2 g MgSO4 bolus i.v. and a 1 g/hour continuous infusion over 6 hours. To evaluate the presence of Mg deficiency, urine was collected from the onset of treatment and continued for the next 24 hours, and the excretion rate of administered Mg was calculated. Ventricular rates were obtained at baseline, after MgSO4 bolus, and every 15 minutes for the first hour. The decrease in the VR was statistically significant at 15, 30 and 60 minutes after Mg therapy (p = 0.0025, p < 0.001, p > 0.001). There was no difference in the response to Mg therapy between Mg deficient and nondeficient patients at 15, 30 or 60 minutes after therapy (p = 0.41, p = 0.28, p = 0.08). It is concluded that i.v. MgSO4 has a statistically significant but clinically limited effect on VR and this effect did not differ between patients with and without Mg deficiency.
authors.affiliation: Emergency Department of Akdeniz University Hospital, Arapsuyu, Antalya, Turkey.
authors.forename: O
authors.initials: O
authors.lastname: Eray
authors.forename: S
authors.initials: S
authors.lastname: Akça
authors.forename: M
authors.initials: M
authors.lastname: Pekdemir
authors.forename: E
authors.initials: E
authors.lastname: Eray
authors.forename: Y
authors.initials: Y
authors.lastname: Cete
authors.forename: C
authors.initials: C
authors.lastname: Oktay
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008274:Magnesium / Q000097:blood* / Q000652:urine; D008275:Magnesium Deficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017180:Tachycardia, Ventricular / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D008278:Magnesium Sulfate; D008274:Magnesium